TITLE: The inclusion complex of 4-hydroxyonenal with a polymeric derivative of beta-cyclodextrin enhances the anti-tumoral efficacy of the aldehyde in several tumor cell lines and in a three-dimensional human melanoma model.

Stefania Pizzimenti\textsuperscript{a,*}, Eric Ciamporcero\textsuperscript{a}, Piergiorgio Pettazzoni\textsuperscript{a,1}, Simona Osella-Abate\textsuperscript{b}, Mauro Novelli\textsuperscript{b}, Cristina Toaldo\textsuperscript{a}, Miriam Husse\textsuperscript{a}, Martina Daga\textsuperscript{a}, Rosalba Minelli\textsuperscript{c}, Agnese Bisazza\textsuperscript{c}, Paolo Ferruti\textsuperscript{d}, Elisabetta Ranucci\textsuperscript{d}, Maria Grazia Bernengo\textsuperscript{b}, Chiara Dianzani\textsuperscript{c}, Fiorella Biasi\textsuperscript{a}, Roberta Cavalli\textsuperscript{b}, Giuseppina Barrera\textsuperscript{a}.

\textsuperscript{a} Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
\textsuperscript{b} Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy
\textsuperscript{c} Department of Drug Science and Technology, University of Turin, Turin, Italy
\textsuperscript{d} Department of Chemistry, University of Milan, Milano, Italy

* Corresponding author:

Stefania Pizzimenti

Department of Clinical and Biological Sciences, Section of General Pathology
University of Turin, Corso Raffaello 30, 10125 Turin, Italy.
E-mail address: stefania.pizzimenti@unito.it
Tel +39-011-6707763

\textsuperscript{1} Present address: Piergiorgio Pettazzoni, Department of Cancer Biology, UT MD Anderson Cancer Center, Houston, TX, USA
ABSTRACT

4-Hydroxynonenal (HNE) is the most studied end product of the lipoperoxidation process, by virtue of its relevant biological activity. The anti-proliferative and pro-apoptotic effects of HNE have been widely demonstrated in a great variety of tumour cells types in vitro. Thus, it might represent a promising new molecule on strategies in anticancer therapy. However, the extreme reactivity of this aldehyde, as well as its insolubility in water, a limiting factor for drug bioavailability, and its rapid degradation by specific enzymes represent the major obstacles for its possible in vivo application. Different strategies can used to overcome these problems. One of the most attractive strategies is the use of nanovehicles, since drug loading into nanosized structures enhances their stability and solubility, thus improving their bioavailability and their anti-tumoral effectiveness. Several natural or synthetic polymers have been used to synthesize nanosized structures and, among them, β-cyclodextrin (β-CD) polymers are playing a very important role in drug formulation by virtue of the ability of β-CD ability to form inclusion compounds with a wide range of solid and liquid molecules by molecular complexation. Moreover, several β-CD derivatives have been designed in order to improve their physicochemical properties and inclusion capacities. Here we report that the inclusion complex of HNE with a derivative of β-CD, the β-CD-poly(4-acryloylmorpholine) conjugate (PACM-βCD), enhances the aldehyde stability. Moreover, the inclusion of HNE in PACM-βCD potentiates its antitumor effects in several tumor cell lines, and in a more complex system, like a human reconstructed skin carrying melanoma tumor cells.

KEYWORDS

4-Hydroxynonenal (HNE)
Nanotechnology
β-Cyclodextrin-poly(4-acryloylmorpholine) conjugate
Tumor cell lines
Three-dimensional human melanoma model
INTRODUCTION

Among different lipid peroxidation-end products, 4-hydroxynonenal (HNE) is the aldehyde most intensively studied by means of its relevant biological activity [1-3]. At micromolar concentrations, similar to those found in human plasma and tissues [4], HNE inhibits cell proliferation, induces differentiation and/or apoptosis [1-2, 5], inhibits angiogenesis [6] and cell adhesion [7], in many tumor cell lines. HNE elicits its biological activities by modulating the expression of oncogenes [8-10], anti-oncogenes [11], transcription factors [12] or apoptotic genes [13-15]. Moreover, HNE is able to affect the unlimited replicative potential of cancer cells, by inhibiting hTERT expression, and consequently telomerase activity, in leukemic and colon cancer cell lines [16, 17]. In the HL-60 human leukemic cell line, the anti-proliferative effect of HNE is also sustained by the modulation of the expression of ten specific miRNAs [11], a class of conserved non-coding small RNAs, which regulate gene expression by translation repression of coding mRNAs [18]. It is very likely that the majority of effects observed on cellular responses can be mediated by the reaction of HNE with biomolecules, such as protein, peptides and, at higher concentrations, with DNA [4, 19]. Quantitatively, proteins, and, among peptides, the GSH, represent the most important group of HNE-targeted biomolecules [4]. The majority of HNE-protein adducts have been identified as enzymes, carriers, receptors, ion channels, transport proteins, cytoskeletal and heat shock proteins. The biological significance of HNE-protein adducts identified have been reviewed by several authors [2, 19]. The HNE adduction occurs through the 1,4-addition (Michael addition) of the nucleophilic groups in cysteine (Cys), histidine (His) or lysine (Lys) residues of the protein, respectively, onto the electrophilic double bond of HNE. Alternatively, Schiff-bases are formed with \( \tilde{\text{U}}\text{NH}_2 \) groups of Lys residues via the C-1 aldehyde group. Michael adducts generally represent \( >99\% \) of HNE protein modifications while Schiff-base adduct formation is less prevalent even in the presence of excess HNE [4, 20, 21].
While the anti-tumoral action of HNE has been widely demonstrated in several tumor cell types in vitro, its effect in in vivo models has been demonstrated in a very limited numbers of papers. For example, Zarkovic and collaborators have demonstrated that HNE, applied to the skin lesions of melanoma in rats, caused a regression of murine melanoma cell growth and an increased rat survival [22].

The extreme reactivity of this aldehyde, as well as its insolubility in water, a limiting factor for drug bioavailability, and its rapid degradation by specific enzymes [23-26] represent the major obstacles for its possible clinical use. Nanotechnological approaches can help to overcome these problems. Drug delivery systems represent an alternative strategy to reformulate bioactive agents in cancer chemotherapy. Old or new drugs can be loaded into nanosized structures (particularly in the range from 10 nm to 100 nm), thus reducing toxic side effects and improving their therapeutic index. Indeed, the drug encapsulation in a carrier may result in various advantages like better bioavailability, system stability, high drug loading, controlled release kinetics, long blood circulation time and selective distribution in the organs/tissues with longer half-life [27]. Nanovehicles used for anticancer drug delivery can be made from a variety of materials, including polymers, liposomes, carbon nanotubes, metals, such as iron oxide and gold, and cyclodextrins (CDs) [28]. The latter have received much attention by virtue of their ability to form non-covalent inclusion complexes with a large variety of guest molecules. CDs are biomaterials consisting of natural cyclic oligosaccharides obtained by enzymatic digestion of starch. They consist of glucopyranose units linked by \( \dot{\text{U}}(1-4) \) bond. In particular, the natural \( \beta \)-cyclodextrin (\( \beta \text{CD} \)), composed of seven glucopyranose units, has been extensively used, by reason of its ready availability and cavity size suitable for the widest range of drugs [29]. However, \( \beta \text{CD} \) has low water solubility (1.85 % w/v at 25 °C) and it is toxic when administered intravenously. Consequently many chemical derivatives have been proposed. Among polymer derivatives, amphiphilic \( \beta \)-CDs have been proposed, due to their extremely low toxicity, excellent biocompatibility, and flexible complexation capacity with poorly soluble molecules [29]. In previous work, it has been
demonstrated that a new derivative of βCD, the β-cyclodextrin-poly(4-acryloylmorpholine) conjugate (PACM-βCD), can be dispersed in water as well as in several organic solvents such as chloroform and lower alcohols [30]. Moreover, in vitro tests showed that it is biocompatible, devoid of hemolytic activity and it is capable of including and solubilizing water poorly soluble drugs [30]. The main aim of the present study is to assess the potential anti-tumoral activity of the inclusion complex of HNE with PACM-βCD (HNE/PACM-βCD). The effects on cell viability, apoptosis and cellular differentiation by HNE/PACM-βCD were tested in vitro on several tumor cell lines, as well as in a more complex system of human reconstructed skin carrying melanoma tumor cells.

MATERIALS AND METHODS

Preparation and characterization of inclusion complex of HNE with PACM-βCD (HNE/PACM-βCD)

HNE (Cayman Europe, Tallin, Estonia) is supplied as solution of 10 mg/ml in ethanol. Firstly this solvent was evaporated through a gentle flow of N₂. A solution of acetic acid (CH₃COOH)/acetone (CH₃COCH₃) (Sigma-Aldrich, Milan, Italy) at 30:70 v/v ratio was added to the dried HNE, in an ice bath and under magnetic stirring. PACM-βCD was synthesized as described elsewhere [30]. PACM-βCD, as powder, was added in a molar ratio 1:1 (HNE: PACM-βCD) to the CH₃COOH/CH₃COCH₃/HNE solution, in order to form the HNE/ PACM-βCD (HNE/ PACM-β) inclusion complex. The complex was then dried under nitrogen (N₂) flow, in an ice bath. The dried complex was stored at -20 °C. Before use, the dried complex was completely dissolved in 3 ml of the physiological Phosphate Buffered Saline solution (PBS, containing 0.01 M phosphate buffer, 0.0027 M potassium chloride and 0.137 M sodium chloride, at pH 7.4; Sigma-Aldrich), after at least 2 hours stirring.
The amount of loaded HNE was determined by the HPLC method as described in the next section, after dilution of HNE/PACM-βCD in an acetonitrile (C$_2$H$_3$N)/CH$_3$COOH mixture (Sigma-Aldrich) (96:4 v/v).

The HNE/PACM-βCD inclusion complex was characterized by Differential Scanning Calorimeter (DSC), by using a DSC/7 differential scanning calorimeter (Perkin Elmer, CT-USA) equipped with a TAC 7/DX instrument controller. The instrument was calibrated with indium for melting point and heat of fusion. A heating rate of 10 °C/min was employed in the 25–300 °C temperature range. Standard aluminium sample pans (Perkin Elmer) were used; an empty pan was used as reference standard. Analyses were carried out under N$_2$ purge; triple runs were done on each sample.

For cell experiment studies, the HNE/PACM-βCD inclusion complex as well as, the empty carrier PACM-βCDs, were sterilized by autoclaving at 121 °C at 2 bar for 15 min, a crucial passage for their in vitro/in vivo use. After autoclaving, the HNE stability on HNE/PACM- βCD was determined by HPLC analysis (see below).

**HNE quantitative analysis in HNE/PACM-βCD**

The quantitative determination of HNE was performed by HPLC analysis using a Perkin Elmer instrument (L2 Binary Pump) with a UV-vis detector. The mixture of HNE/PACM-βCD with the C$_2$H$_3$N/CH$_3$COOH solution, previously described, was separated by HPLC at the following conditions: RP-18 column (Merck, Darmstadt, Germany), C$_2$H$_3$N /water (H$_2$O) 42:58 (v/v) as mobile phase, 1.0 ml/min flow rate, 223 nm optical density UV detector setting with 0.05 absorbance units for full recorder scale, 20 εM injected sample volume. Peak identification and quantification was based on reference chromatograms and a calibration curve obtained from standard HNE solutions (1 to 10 mM) in H$_2$O / C$_2$H$_3$N / CH$_3$COOH. The HPLC chromatography system, equipped with an UV-Vis detector and the analytical software were from Waters S.p.A. (Vimodrone, Milan, Italy).
**In vitro release study**

The *in vitro* release experiments were performed in PBS buffer at pH 7.4 at 37 °C using the dialysis bag technique. About 10 mg of HNE/PACM-βCD were dispersed in 3 ml of PBS buffer at pH 7.4 and then placed in a dialysis bag obtained using a dialysis membrane with cut-off 3500 Da (Spectralpor, Spectrum Lab. Inc., Breda, The Netherlands). The dialysis bag was then placed in 15 ml of PBS solution and incubated at 37 °C under stirring. At fixed times within a period of 2 h, samples were collected and replaced with fresh PBS solution. The concentration of released HNE was determined by HPLC analysis, as described above.

**Stability of HNE/PACM-βCD complex over time**

The stability of HNE loaded in PACM-βCD, stored at -20 °C, was determined over time by HPLC analysis, as described above, for a period of 12 months.

**Evaluation of HNE-His Michael adducts on BSA by Western Blot**

10 μg of BSA diluted in PBS was incubated with 10 μM free HNE, 10 μM HNE/PACM-βCD, PACM-βCD at 37°C for 45 min. Aliquots were then removed from the solutions and HNE-His Michael adducts were measured via Western Blot, as described in *Lysate preparation and Western Blot analysis* section of Materials and Methods. The monoclonal primary antibody anti-HNE-His adduct was a kind gift of Prof. Uchida. Ponceau red staining was used to confirm equal protein loading.

**Preparation and characterization of 6-coumarin PACM-βCD inclusion complex**

To obtain a fluorescent formulation 6-coumarin PACM-βCD inclusion complex was prepared and characterized by DSC and fluorescent spectroscopy as elsewhere described [31].

---

7
Cell Culture and Treatments

Human prostate cancer PC-3, human melanoma A375, human leukemia HL-60 and U937, colon carcinoma HT-29 and murine renal cell carcinoma (RenCa) cell lines were obtained from European Collection of Cell Cultures (ECACC). They were cultured at 37 °C in a humidified atmosphere of 5% CO₂-air. All these cells were grown, in RPMI 1640 medium supplemented with 2 mM glutamine, 1% antibiotics and 10% FCS (Lonza).

The treatments with free HNE were performed after the following steps: after evaporating the solvent through a gentle flow of N₂, the aldehyde was then resuspended in sterile PBS. The concentration was measured by spectrophotometer by recording the absorbance of an aliquot of HNE diluted 1:200 in H₂O at 223 nm (ε=13,750). Cell cultures were treated with a final concentrations of 1, 5 and 10 μM of free HNE or HNE/PACM-βCD, prepared as previously described. Moreover, all the cell lines were treated with empty inclusion complex PACM-βCD (for the preparation see above), at dilutions corresponding to that of HNE-loaded inclusion complex.

Cell proliferation and viability

The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay is a colorimetric assay used to determine the level of metabolic activity in cells, able to reduce the yellow tetrazolium dye MTT to purple formazan crystals. The amount of formazan produced provides an indication of the mitochondrial integrity and activity which, in turn, may be interpreted as a measure of both cell viability and cell proliferation [32]. Cells were seeded (1.5×10³ - 5× 10⁵ cells/well) in 96-well plates, in 200 μl of serum-supplemented medium and were treated with the compounds 24 h later. At the indicated times, 30 μl MTT dye solution (5 mg/ml in PBS) was added to each well, and the plate was incubated for 3 h at 37°C. After removal of the medium, 150 μl of dimethyl sulphoxide (DMSO) (Sigma-Aldrich) was added to each well to dissolve the formazan crystals and the absorbance was red at 540 nm on a ELISA plate reader (Perkin Elmer). Each group was analyzed in quadruplicate samples.
Cell viability was evaluated by trypan blue exclusion test also, which is based on the principle that live cells possess intact cell membranes that exclude certain dyes, such as trypan blue. Briefly, cells were plated \((1.5 \times 10^2 - 4 \times 10^4 \text{ cells/wells})\) in 96-well plates, in 200 μl of serum-supplemented medium and were treated with the compounds 24 h later. At the indicated time, a collection of supernatants and adherent cells, obtained by trypsinization, were incubated in 0.4% trypan blue and pipetted onto a Bürker chamber. Stained dead and non-stained viable cells were counted in a microscope and the percentage of live cells was calculated for each experimental condition. Moreover, the viable cells were determined by counting, in a Bürker chamber, the number of non-stained viable cells after trypan blue addition at the indicated time.

**Lysate preparation and Western blot analysis**

5x10^5 HL-60, PC3 and A375 cells were collected 24 h after the treatments, and washed once in cold PBS, pH 7.4. Total extracts were prepared by lysis in a buffer containing 20 mM Tris–HCl pH 7.4, 5 mM EDTA, 150 mM NaCl, 1% v/v Triton X-100, phosphatase (P2850, Sigma–Aldrich), and protease (Sigma–Aldrich P8340) inhibitor cocktails, incubating them for 15 min at 4 °C. After high-speed centrifugation (10,000 rpm for 15 min at 4 °C), the supernatants were collected, and the protein concentration was determined in triplicate by using a commercially available kit (Bio-Rad Laboratories, Segrate, Milan, Italy). Western blot analysis was performed using home-made 9.3% SDS polyacrylamide gels (Bio-Rad Laboratories). Proteins (20 μg) were mixed with 20 μl of Laemmli sample buffer (161-0737, Bio-Rad Laboratories) containing 10% 2-mercaptoethanol, boiled for 5 min, and loaded into the gels. The run was performed at the constant voltage of 100 V. The proteins were then transferred onto a nitrocellulose membrane with a semidry transfer apparatus (Biometra, Goettingen, Germany). The membranes were subsequently incubated for 1 h with 5% non fat dry milk dissolved in TBSİ Tween 20 for saturation of nonspecific binding sites, and incubated overnight at 4 °C with the primary antibodies against the cleaved poly (ADP-ribose) polymerase (PARP) (AB3620, Merck-Millipore, Darmstadt, Germany), or against anti-β-actin
(A1978, Sigma-Aldrich). The membranes were washed three times with TBS-Tween 20, and incubated with horseradish peroxidase (HPR)-conjugated secondary antibodies (Bio-Rad Laboratories) for 1 h at room temperature. The detection of the bands was carried out after reaction with chemiluminescence reagents (PerkinElmer NEL105001EA) through film (sc-201697, Santa Cruz Biotechnology, Heidelberg, Germany) autoradiography.

**HL-60 cell differentiation**

Nitroblue tetrazolium (NBT, Sigma-Aldrich) assay was used as a functional measure of the maturation of HL-60 as described by Collins [33] with some modifications. The reduction of NBT to insoluble blue formazan granules occurs during the stimulus-induced respiratory burst of mature granulocytes and is routinely used as an indicator of the extent of granulocytic differentiation of HL-60 acute promyelocytic leukemia cells. Thus, this method allows the detection of differentiated cells capable of producing Reactive Oxygen Species (ROS) as a result of appropriate stimulus, such as phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich). Approximately 5 x 10^5 cells were resuspended in 0.5 ml PBS containing NBT (200 nM) and PMA (500 nM), the activating agent, and incubated at 37°C for 30 min. 1 N HCl (Sigma-Aldrich) was added to the samples to stop the reaction. The formazan precipitate was solubilized in DMSO and the mixture was transferred to 96-well plates.

The extent of the reaction was evaluated, at 72 and 96 h, by spectrophotometry reading at 570 nm wavelength, on an ELISA plate reader. Results were normalized with the viable cell number and results are expressed in arbitrary units, placing the value 1 to the untreated control cells.

**Measurement of HNE disappearance from medium**

10 μM HNE/PACM-βCD or 10 μM free HNE were added to 0.5 ml of RPMI medium with 10% fetal calf serum (FCS) (Lonza, Milan, Italy) and maintained at 37 °C in a humidified atmosphere of
5% CO₂. After 0, 5, 15, 30 min, aliquots of medium were added to an equal volume of C₂H₃N / CH₃COOH 96:4 (v/v). HNE content was determined by HPLC analysis, as described above.

**Measurement of HNE disappearance from HL-60 cell suspension**

HL-60 cells (5x10⁵) were incubated with 10 µM HNE/PACM-βCD or 10 µM free HNE in RPMI medium with 10% FCS (Lonza) and maintained at 37 °C in a humidified atmosphere of 5% CO₂. After 0, 5, 15, 30 min, aliquots of the homogeneous cellular suspensions, were collected for HPLC analysis, as described above.

**Evaluation of PACM-βCD cellular uptake by confocal laser scanning microscopy in HL-60, PC3 and A375 cells**

Exponentially growing HL-60, PC3 and A375 cells were incubated with 1 µg/ml of fluorescent labeled 6-coumarin PACM-βCD inclusion complex for 1, 5 and 45 min. The living cells were suddenly observed with a LSM 510 confocal laser microscope (Carl Zeiss SpA, Arese, Milan, Italy), using a plan neofluar lens 20×/0.5 and 40×/0.75 (zoom 2X). The instrument was set to 488 nm exciting laser band, with a 505ï 530 nm band pass emission filter. Exciting light intensity, black level, and photomultiplier gain were adjusted on control specimens; settings were kept the same when scanning experimental samples. Images were elaborated using LSM 510 Image Examiner software (Carl Zeiss SpA). The assay was performed on not fixed living cells, to avoid possible artefacts due to the protocols of cell fixation.

**Detection of HNE-His adducts by immunofluorescence in HL-60 cells**

HL-60 cells (5x10⁵) were incubated with 10 µM of free HNE or HNE/PACM-βCD. After treatments, cells were collected at the indicated time, centrifuged and the pellets were fixed for 15 min in 4% paraformaldehyde. Aliquots were smeared onto a non-charged slide and dried. Thereafter the cells were permeabilized with 1% Triton X-100 for 30 min at room temperature and
washed with PBS. Then, the slides were incubated with 1% BSA in PBS for 30 min at room temperature, after which they were incubated for 1 h at room temperature with the primary monoclonal antibody against HNE-His adducts (a generous gift from Prof. Uchida, 1:100 in 1% BSA dissolved in PBS). The slides were subsequently washed, incubated for 1 h at room temperature with the secondary fluorescein isothiocyanate (FITC)-conjugated antibody (Invitrogen, AlexaFluor488 Goat anti mouse IgG, diluted 1:100 in 0.1%BSA in PBS), washed again and mounted on coverslips. The images were captured using an epi-illuminated fluorescence microscope (Axiovert 35; Carl Zeiss MicroImaging GmbH, Jena, Germany), using a plan neofluar lens 40x/0.75.

**Melanoma 3D cultures**

Culture inserts of a differentiated, full-thickness, three-dimensional skin reconstruction model of A375 melanoma cells were purchased from MatTek (Ashland, MA). These culture inserts were prepared by culturing mixed suspensions of normal human epidermal keratinocytes and A375 melanoma cells at a 1:10 ratio on fibroblast-contracted collagen gels and allowing differentiation for ~1 week. The 3-D tissues are fed only through the basolateral (bottom) surface, where there is the dermal compartment, which remains in contact with the culture medium, while the apical (top) surface of the tissues, corresponding to the cornified epidermal layer, is directly in contact with the air. Culture inserts were then incubated in duplicate with serum-free medium containing 10 μM HNE/PACM-βCD, 10 μM free HNE and the empty inclusion complex PACM-βCD, at the dilution corresponding to that of HNE-loaded inclusion complex, or PBS for control. The medium was replenished every other day, and cell cultures were collected on days 0, 3 and 8 from the beginning of the treatments and fixed with 10% formalin.

For cell morphology analysis, culture inserts were paraffin embedded, serial sectioned, and analyzed by haematoxylin and eosin (H&E) staining. Serial sections were observed under a 10x/1.30 NA objective lens using Olympus BX51 microscope. Images were captured using high-

For immunohistochemistry, sections were deparaffinized in xylene and rehydrated through graded decreasing concentrations of alcohol. Antigen retrieval was carried out in citrate buffer pH 6 by heating in a pressure-cooker. The sections were then stained with antibodies specific for the detection of S100 (rabbit polyclonal, DAKO, Milan, Italy) and Ki-67 (Mib-1 Clone, DAKO). Appropriate positive and negative controls were included for each antibody test. Ki-67 positively stained cells were counted in six different fields of each slide (observed with Olympus BX51 microscope), whereas S-100 quantification was performed on digitally acquired images with Photoshop CS5 program. Results have been expressed in percentage with respect to the controls.

Statistical analysis
Data were expressed as the mean ± SD. Significance between experimental groups was determined by one-way ANOVA followed by the Bonferroni's multiple comparison post test using GraphPad InStat software (San Diego, USA). Values of $p \leq 0.05$ were considered statistically significant.

RESULTS

Preparation and characterization of the inclusion complex of HNE with PACM-βCD
The chemical structure of the PACM-βCD conjugate, obtained as previously described [30] is shown in the upper part of Fig. 1A. This conjugate carries a single β-CD moiety at one terminus, characterized by a lipophilic inner cavity and a hydrophilic outer surface, and the PACM chain as an amphiphilic tail. This conjugate, acting as a nanocarrier, is able to solubilize considerable
amounts of poorly soluble drugs and slowly release them, as demonstrated in the case of Acyclovir [30]. At the bottom of Fig 1A, a schematic representation of HNE/PACM-βCD is reported. HNE, the guest molecule, is hosted inside the toroidal structure of the βCD ring. The host-guest molar ratio is 1:1.

In Fig. 1B the preparation scheme used to prepare HNE/PACM-βCD is presented. This conjugate has an average molecular weight in the order of 10^4 Dalton. Thus, their β-CD content is approximately 10% by weight. PAMC-βCD was able to encapsulate HNE forming a stable inclusion complex. The HNE/PACM-βCD complex gave a clear system after dispersion in water. The HNE loading was about 18% on a weight to weight basis with an encapsulation efficiency of 83.5%.

DSC analysis of HNE/PACM-βCD confirmed the HNE complexation (data not shown). Moreover, we demonstrated by HPLC determination that the HNE/PACM-βCD complex can be stored for 12 months at -20 °C without HNE degradation and after autoclaving procedures (data not shown). The inclusion complex HNE/PACM-βCD is stable with a high value of association constant (data not shown). This feature has been also demonstrated by analyzing the in vitro release profile of HNE from HNE/PACM-βCD in PBS at pH 7.4, to mimic physiological conditions (Fig. 2A). The in vitro release profile showed a pseudo-zero order kinetic with no initial burst effect. Under the experimental conditions adopted, about 6% (w/w) of the drug was released in 2 h, while after 24 h a HNE release of about 30% (w/w) was observed.

Moreover, in order to check the level of protection being offered by the nanocarrier PACM-βCD, we measured the ability of HNE to form Michael adducts with His residues of BSA by Western Blot (Fig. 2B). A very strong band of ~60 kDa can be observed only after the incubation of BSA with 10 μM free HNE, while a faint immunoreaction was observed when BSA was incubated with 10 μM HNE/PACM-βCD. No immunoreaction was observed in control samples (BSA alone or BSA incubated with the empty carrier PACM-βCD).
**HNE/PACM-βCD inhibits cell viability and cell growth in tumor cell lines of several different tissue origins**

Figures 3-5 show the amount of viable cells, measured by MTT metabolic assay, after HNE/PACM-βCD treatments, at the concentrations indicated, in tumor cell lines of several different tissue origins. In these cell lines the effects on cell viability were compared to those obtained by incubating tumor cell lines with free HNE, at the same concentrations, and with the empty carrier PACM-βCD, at dilutions corresponding to that of HNE-loaded inclusion complex.

In all the cell lines tested, 10 μM HNE/PACM-βCD significantly reduced the amount of viable cells, not only in comparison with untreated control cells, but also with respect to cells treated with 10 μM free HNE.

Human prostate cancer PC-3 cells and human melanoma A375 cells (Fig. 3), human leukemia HL-60 and U937 cells (Fig. 4), were the most sensitive. In these cells, 5 μM HNE/PACM-βCD was still effective in reducing the amount of viable cells, while all the treatments with 1 μM were ineffective.

In colon carcinoma HT-29 and murine renal carcinoma RenCa cells (Fig. 5), only HNE/PACM-βCD 10 μM treatments were able to reduce the amount of viable cells.

The treatment with the empty PACM-βCD did not affect the amount of viable cells in any cell lines tested.

Cell viability was analyzed by trypan blue exclusion test also, in HL-60, PC3 and A375 cell lines, the most sensitive cell lines. All three cell lines were treated with the highest concentration of compounds (10 μM) and cell viability was analyzed at 24 h - 48 h and 72 h (Fig. 6A). In all the three cell lines, 10 μM HNE/PACM-βCD significantly inhibited cell viability at 48 h and 72 h. Moreover, at 72 h this inhibition was significant not only in comparison with untreated control cells, but also with respect to cells treated with 10 μM free HNE. A modest but significant inhibition of cell viability was observed in PC3 and A375 cell lines at 72 h after 10 μM free HNE treatment.
Cell growth inhibition was evaluated in HL-60, PC3 and A375 cell lines with the highest concentration of the compounds, by counting the number of non-stained viable cells at the indicated time (Fig. 6B). Results demonstrated that in 10 μM HNE/PACM-βCD treated cells, the growth was more reduced with respect to cells treated with 10 μM free HNE.

**HNE/PACM-βCD induces apoptosis in PC3, A375 and HL-60 cell lines**

In consideration of the great effect on cell viability and cell proliferation, we decided to investigate a possible pro-apoptotic role of HNE/PACM-βCD by studying the presence of cleaved PARP, a hallmark of the terminal apoptotic cascade (Fig. 7). HL-60, A375 and PC3 cell lines, which previously showed great sensitivity toward HNE, where analyzed. Western blot analysis, performed 24 h after cell treatments, revealed an 85-kDa band, corresponding to the main fragment of cleaved PARP, in all the cell lines, after 10 μM HNE/PACM-βCD treatment. A weak band was detected in A375 and a very faint one in PC3 cells treated with 10 μM free HNE, while apoptosis was not present in untreated control cells, as well as in PACM-βCD treated cells.

**HNE/PACM-βCD induces differentiation in the HL-60 cell line**

HL-60 cells are a tumor cell line well known for differentiation studies. Moreover in our laboratories we have demonstrated the differentiative effect of 1 μM HNE repeatedly added (10 treatments every 45 min) to HL-60 cell suspension [34]. Thus, these previous results prompted us to investigate a possible differentiative effect of HNE/PACM-βCD in the HL-60 cell line. The results were compared to those obtained by treating cells with the empty carrier PACM-βCD, with 10 μM free HNE (a single treatment, HNE ST 10 μM), with 1 μM free HNE repeatedly added (10 treatments every 45 min, HNE RT 1 μM) and with 1.25% DMSO, a well known inducer of differentiation (Fig. 8).

The differentiation was evaluated by the NBT test and the results are expressed in arbitrary units, placing the value 1 to the untreated control. As shown in Fig. 8, 10 μM HNE/PACM-βCD
treatments induced HL-60 differentiation, similarly as obtained by DMSO and HNE-RT. The single treatment with 10 μM free HNE (HNE ST 10 μM) was not sufficient to induce the differentiation program, since the values are very similar to those obtained in untreated controls. Finally, the empty carrier PACM-βCD did not induce HL-60 cell differentiation.

*The HNE/PACM-βCD inclusion complex protects HNE from the reaction towards proteins contained in the medium with FCS.*

In order to establish whether HNE loaded into the PACM-βCD inclusion complex is more stable in the culture medium containing FCS with respect to free HNE, we measured its rate of disappearance by HPLC (Fig. 9A). HPLC analysis can detect only reactive and free HNE, not already bound to other molecules, thus it is possible to measure molecules of aldehyde still capable of binding to molecular targets. The concentration of HNE was measured in culture medium containing serum, after the addition of 10 μM HNE/PACM-βCD or 10 μM free HNE at 5, 15 and 30 min. At 5 min a non significant difference was already present between the two samples: reactive HNE level was higher in the medium treated with 10 μM HNE/PACM-βCD with respect to 10 μM free HNE treated medium (about 95% and 80% of remaining HNE in 10 μM HNE/PACM-βCD and 10 μM free HNE treated medium, respectively). After 15 min, HNE loaded in the PACM-βCD inclusion complex was almost entirely present in the medium (about 90% of remaining HNE), while free HNE was greatly diminished (about 60% of remaining HNE). At 30 min more than 70% of HNE was still present, if protected by the nanocarrier, while free HNE almost totally disappeared (about 20% of remaining HNE).

*PACM-βCD nanocarrier preserves HNE reactivity in HL-60 cell suspension*

The rate of disappearance of reactive HNE was also measured in a homogenous cellular suspension of HL-60 cells after 10 μM HNE/PACM-βCD addition, in comparison with data obtained by treating HL-60 cells with 10 μM free HNE (Fig. 9B). At 5 min a dramatic decrease in reactive HNE
content was observed in the cell suspension treated with 10 \( \mu \)M free HNE (about 55\% of remaining HNE), while in the cell suspension, treated with 10 \( \mu \)M HNE/PACM-\( \beta \)CD, HNE there was a slight decrease (about 90\% of remaining HNE). At 15 min the reactive HNE level decreased in both conditions, but more consistently in the cell suspension treated with 10 \( \mu \)M free HNE (about 80\% and 30\% of remaining HNE in 10 \( \mu \)M HNE/PACM-\( \beta \)CD and 10 \( \mu \)M free HNE treated cells, respectively). At 30 min a similar diminishing trend was observed; however, although at 30 min the reactive HNE level in cell suspension treated with 10 \( \mu \)M HNE/PACM-\( \beta \)CD decreased by half compared to its level at 15 min, its concentration was significantly higher with respect to that measured in the cell suspension treated with 10 \( \mu \)M free HNE (about 40\% and 13\% of remaining HNE in 10 \( \mu \)M HNE/PACM-\( \beta \)CD and 10 \( \mu \)M free HNE treated cells, respectively).

**PACM-\( \beta \)CD inclusion complex is rapidly internalized within cells.**

The penetration of our formulation inside the cells was evaluated in HL-60, A375 and PC3 tumor cell lines. The fluorescent labeled 6-coumarin PACM-\( \beta \)CD inclusion complex was added to the cell suspensions and evaluated by confocal laser scanning microscopy at 1, 5 and 45 min in fresh cells (Fig. 10).

In all the cell lines, the 6-coumarin PACM-\( \beta \)CD inclusion complex immediately came inside the cells (within 1 min, data not shown). After 5 min cell incubation, the distribution was cytoplasmatic and similar results were obtained at 45 min after the treatment. Fluorescence was not detected in cells not exposed to labeled PACM-\( \beta \)CD inclusion complex (data not shown).

**Inside cells, HNE loaded in PACM- \( \beta \)CD is released from the nanocarrier and reacts with proteins.**

In order to investigate the ability of PACM- \( \beta \)CD inclusion complex to release HNE inside cells, thus rendering it able to react with intracellular targets, we analyzed the presence of HNE protein adducts in HL-60 cells at 5, 15 and 45 min after treatments with 10 \( \mu \)M HNE/PACM- \( \beta \)CD. Results were compared to those obtained by treating HL-60 cells with 10 \( \mu \)M free HNE. HNE-His adducts
were detected by immunofluorescence and representative results are showed in Fig. 11. Five min after 10 μM free HNE addiction, HNE-protein adducts can be located mainly on the surface of the plasma membrane, while in 10 μM HNE/PACM-βCD treated cells we observed a weak immunofluorescence signal. After 15 min, both cells treated with 10 μM free HNE and 10 μM HNE/PACM-βCD showed HNE-protein adducts. The same feature was observed at 45 min. No traces of HNE-adducts were detected in not-treated control cells (data not shown).

**HNE/PACM-βCD inhibits melanoma cell growth in a human 3D culture**

As previously reported in this paper, HNE/PACM-βCD greatly inhibits the A375 human melanoma tumor cell line (Fig. 3). This prompted us to investigate the effect of HNE/PACM-βCD on a more complex experimental model, such as the three-dimensional skin reconstruction model of A375 melanoma cells. Culture inserts were incubated in duplicate with serum-free medium containing PBS (Control), 10 μM HNE/PACM-βCD, 10 μM free HNE or the empty carrier PACM-βCD, at the dilution corresponding to that of the HNE-loaded inclusion complex. The medium was replenished every other day and cell cultures were collected before the treatment (day 0) and on days 3 and 8 from the beginning of the treatments. H&E staining of day 0 cultures (data not shown) revealed keratinocytes in the upper epidermal layer, organized in the basal, spinous, granular and corneum stratum; a second distinct layer of cells was represented by A375 melanoma cells. At this early time point, this layer is only a few cells thick, and these cells are distinguished by their dark nuclear staining. The third distinct layer is represented by fibroblast-contraspillo collagen, the dermal stratum. Over time, in control culture inserts, the metastatic melanocytes proliferate and develop nodules by day 3 (data not shown), larger at day 8 (Fig. 12). In contrast, at day 8, culture treated with 10 μM HNE/PACM-βCD had smaller tumor nodules and remain closer to the epidermidis with lower invasion of the dermal structures. Intermediate results were obtained at day 8 with 10 μM free HNE; at this time tumor nodules were smaller than those observed in control specimens, but larger than those observed in 10 μM HNE/PACM-βCD treated culture inserts. Finally, conditions similar
to those observed in control culture inserts were obtained in PACM-βCD-treated 3D cultures (Fig. 12).

The analysis for the expression of the S100 protein, a marker of melanocytes/melanoma cells, confirmed the presence of melanoma cells in the tissues. Fig. 13 reveals strong expression of S-100 in control culture inserts, as well as in tissue cultures treated with the empty vehicle PACM-βCD. In contrast, 10 µM HNE/PACM-βCD significantly inhibited S-100 expression, while with free HNE we observed intermediate results. These observations were quantified and the densitometric results are presented in Fig. 14. To determine whether the decrease of S-100 positive cells might account for the inhibition of melanocyte proliferation, tissue sections were stained with the proliferation marker Ki-67. The Ki-67 staining (Fig. 13) clearly reveals a decrease in the number of proliferative cells after treatment with 10 µM HNE/PACM-βCD, with respect to control or PACM-βCD-treated tissues. Intermediate results were obtained, again, with free 10 µM HNE treatments. A quantitative analysis of the immunohistochemical results of Ki-67 is presented in Fig. 14.

The nanotechnological formulation did not have toxic effects on normal cells, such as fibroblasts and keratinocytes making up the three dimensional tissue.

**DISCUSSION**

The results presented in this experimental work demonstrate that PACM-βCD conjugate was able to complex HNE, improving the water solubility and stability of the lipophilic aldehyde. The *in vitro* release results indicated a very slow release rate for HNE, demonstrating a stable host-guest non-covalent interaction. When HNE is inside the PACM-βCD nanocarrier, it is not able to form Michael adducts with proteins, one of the key events in the biological responses to the aldehyde. Moreover, in the medium containing FCS, in presence or in absence of cells, the nanocarrier keeps the reactive groups of HNE in a free form, not bound to other molecules. All these results strongly
suggest that HNE, loaded in the PACM-βCD nanocarrier, is more protected from its degradation, catabolization or reaction towards extracellular targets.

As soon as PACM-βCD is added to a cellular suspension, the nanocarrier is rapidly internalized into the cells (within 1 min), as demonstrated from results obtained by confocal microscopy. Although it is not possible, for technical reason, to mark with a fluorescent dye, such as 6-coumarin, the PACM-βCD carrying HNE, we succeeded in demonstrating the release of HNE inside the cells after 10 μM HNE/PACM-βCD treatment, through the detection of HNE-protein adducts. Indeed, we have previously demonstrated that PACM-βCD protects HNE from the reaction with proteins; thus, the presence of HNE-protein adducts inside cells strongly suggests that HNE was released from the nanocarrier a few minutes after uptake. Moreover the time course of adduct formation indicated that there were differences in the rate of adduct formation between samples treated with free HNE and HNE/PACM-βCD. As already demonstrated in our laboratories [7], free HNE rapidly enters inside cells, by diffusing through cell membranes, so that it is immediately able to form HNE-protein adducts in particular with plasma membrane and cytosolic proteins. Afterwards HNE-protein adducts are more distributed inside cells, forming adducts after 2 h also in the nuclear compartment [7]. The HNE loaded in the PACM-βCD, being protected by the nanocarrier, is not immediately able to form HNE-protein adducts in the first minutes. However, progressively, HNE can be released from PACM-βCD and by 15 min on it is possible to observe widespread HNE-protein adducts, similar to that obtained in 10 μM free HNE treated cells.

The enhanced stability of HNE, when residing in the nanocarrier, elicited greater biological effects than free HNE in the tumor cell lines analyzed. Indeed, HNE/PACM-βCD was more effective in reducing cell viability and cell growth with respect free HNE, in all the cell lines tested. Moreover, we have demonstrated that 10 μM HNE/PACM-βCD induced apoptosis in HL-60, PC3 and A357 cells at 24 h, while the contribution of apoptosis in affecting cell viability is very small or completely absent in free HNE treated cells. These results are in agreement to those obtained with the trypan blue assay, where an increase of cell death can be observed after 10 μM HNE/PACM-
CD treatments at 48 h and, more consistently, at 72 h, compatible with a secondary necrosis. A similar observation can be made for PC3 and A375 treated with 10 \( \mu \)M free HNE, where faint bands of cleaved PARP can be observed at 24 h in both cell lines, paralleling a weak, but significant, increase of stained trypan blue cells at 72 h. Further, in HL-60 cells, we have demonstrated that 10 \( \varepsilon \)M HNE/PACM-\( \beta \)CD induced not only apoptosis but also cellular differentiation, while a single treatment with 10 \( \varepsilon \)M free HNE did not. We previously demonstrated that differentiation induction occurred when HL-60 cells were maintained for 7.5 h in presence of 1 \( \varepsilon \)M HNE through the protocol of repeated treatments [34]. Thus, it appears that the activity in the induction of cell differentiation, which has been found to be higher in 10 \( \varepsilon \)M HNE/PACM-\( \beta \)CD than in 10 \( \varepsilon \)M free HNE treatment, can be related to the increased permanence of the aldehyde in the cell culture.

Considering the overall results on cellular responses, we can suggest that the protection offered by the nanocarrier to the HNE molecule, allows avoidance of nonspecific interactions with extracellular serum protein, the introduction into cells of a greater number of molecules of reactive HNE and the slow-down of HNE catabolism, with a consequent increase of its biological effectiveness.

Advanced melanoma remains one of the most challenging cancers, in consideration of its resistance to chemotherapy and innovative formulation surely constitutes an innovative therapeutical approach [35]. Thus, results obtained on the human melanoma model are very encouraging, demonstrating a greater inhibitory effect of HNE/PACM-\( \beta \)CD with respect to free HNE. The use of a complex experimental model, such as the 3D tissue culture permits creation of a greater similarity between the cultured cells and the living organism. Thus, the reconstruction of the tissue architecture constitutes a relevant feature in increasing the predictability of the experimental model [36]. The effects obtained with HNE/PACM-\( \beta \)CD on melanoma tissues are of particular interest, also in consideration of the absence of toxic effects on normal tissues, observed in this experimental work. Indeed, the HNE effect seems to be higher in more undifferentiated melanoma cells with respect to
differentiated normal tissues (epidermal keratinocytes and dermal fibroblasts). These results are in agreement with previous works demonstrating the differing ability of HNE to inhibit proliferation of cells with different degree of differentiation [37]. Moreover, other authors have demonstrated that HNE was more effective in affecting cell proliferation of neoplastic cells with respect to the normal phenotype. For instance, it has been demonstrated that human peripheral blood lymphocytes are more resistant to HNE with respect to human lymphocytic leukemia cells [39] and that HNE is able to eradicate human leukemia stem cells, while it is ineffective on normal erythroid or myeloid progenitors [40]. The same feature has been also observed in solid tumors; indeed, it was demonstrated that HNE was more toxic to osteosarcoma cell lines compared to primary cultures of human osteoblasts [41].

It is well established that cancer cells with increased levels of ROS are more vulnerable to damage by further ROS insults induced by exogenous agents [41]. Indeed, many chemotherapeutic agents induce apoptosis through ROS formation [42], as well as through the induction of lipid peroxidation, generating numerous electrophilic aldehydes, such as HNE [43]. Thus, HNE, during conventional anticancer therapies, can be produced on site and contribute to the process of elimination of tumor cells. Although ROS and HNE have been suggested to be involved in the initiation of cancers, so that the increased oxidative stress is considered as an adverse event, recent papers have indicated that the increasing of oxidative stress can be a novel strategy in cancer therapy [44]. These observations further support the possible use of HNE/PACM-βCD as an anticancer drug in vivo.

REFERENCES


ACKNOWLEDGEMENTS

This work was supported by University of Turin (ex 60%, to S.P.) and by Progetti di Ricerca di Ateneo Ï Anno 2011 (to G.B.). We thank Dr. Paola Gamba and Dr. Gabriella Testa for assistance on confocal imaging.
FIGURE LEGENDS

**Figure 1** (A) Up: chemical structure of β-cyclodextrin-poly(4-acryloylmorpholine) conjugate; down: schematic representation of HNE/PACM-βCD (B) Stepwise schematic representation of the HNE/PACM-βCD conjugate preparation.

**Figure 2** (A) *In vitro* release profiles of HNE from PACM-βCD complex in phosphate buffer at pH 7.4. (B) Western blot of anti HNE-His Michael adduct antibody from addition of different HNE formulations to a BSA solution. Lanes: (1) untreated BSA, (2) PACM-βCD (3) 10 μM HNE, (4) 10 μM HNE/PACM-βCD. Ponceau red staining was used to confirm equal protein loading.

**Figure 3** Cell viability evaluated by MTT assay in PC3 and A375 cells. Cell lines were untreated (control) or treated with 10, 5, 1 μM free HNE or HNE/PACM-βCD or PACM-βCD at the time indicated. ■ control; ○ PACM-βCD; ● HNE/PACM-βCD; ▲ HNE. Results are presented as mean ± SD for four independent experiments. *p<0.05, **p<0.01 vs. control; △p<0.05, △△p<0.01 vs. PACM-βCD.

**Figure 4** Cell viability evaluated by MTT assay in HL-60 and U937 cells. Cell lines were untreated (control) or treated with 10, 5, 1 μM free HNE or HNE/PACM-βCD or PACM-βCD at the time indicated. ■ control; ○ PACM-βCD; ● HNE/PACM-βCD; ▲ HNE. Results are presented as mean ± SD for four independent experiments. *p<0.05, **p<0.01 vs. control; △p<0.05 vs. PACM-βCD.

**Figure 5** Cell viability evaluated by MTT assay in HT-29 and RenCa cells. Cell lines were untreated (control) or treated with 10, 5, 1 μM free HNE or HNE/PACM-βCD or PACM-βCD at the time indicated. ■ control; ○ PACM-βCD; ● HNE/PACM-βCD; ▲ HNE. Results are presented as
mean ± SD for four independent experiments. *p≤0.05, **p≤0.01 vs. control; †p≤0.05, ††p≤0.01 vs. PACM-βCD.

**Figure 6** (A) Cell viability evaluated by trypan blue exclusion test in HL-60, PC3 and A375 cells. Cell lines were untreated (control, C) or treated with 10 μM HNE/PACM-βCD, PACM-βCD or 10 μM free HNE at the time indicated. Results are expressed in percentage, as mean ± SD for four independent experiments. *p≤0.05, **p≤0.01 vs. control; †p≤0.05, ††p≤0.01 vs. PACM-βCD. (B) Number of viable cells. Cell lines were untreated (control, C) or treated with 10 μM HNE/PACM-βCD, PACM-βCD or 10 μM free HNE at the time indicated. Results are expressed as number of viable cells x 10^3 / ml for HL-60 cells and as number of viable cells for PC3 and A375. The mean ± SD for four independent experiments was calculated. *p≤0.05, **p≤0.01 vs. control; †p≤0.05, ††p≤0.01 vs. PACM-βCD.

**Figure 7** Apoptosis induction in HL-60, PC3 and A375 cells. Western blot analysis of cleaved PARP in HL-60, PC3 and A375 cells in untreated control cells (lane A), treated with 10 μM HNE/PACM-βCD (lane B), or PACM-βCD (lane C), or 10 μM free HNE (lane D) at 24 h. The same blot was hybridized with anti-β-actin as loading control.

**Figure 8** Differentiation induction on HL-60 cells. Cells were untreated (control, C) or treated with 10 μM HNE/PACM-βCD, or with the empty carrier PACM-βCD, or with 1 μM HNE repeatedly added (10 treatments every 45 min, HNE RT 1 μM), or with 10 μM free HNE (a single treatment, HNE ST 10 μM), or with 1.25% DMSO (DMSO) for 72 h or 96 h. Cell differentiation was determined by NBT test. Results are presented as mean ± SD for three independent experiments. **p≤0.01 vs. control; ††p≤0.01 vs. PACM-βCD.
Figure 9 (A) HNE disappearance in RPMI medium with 10% FCS. 10 μM HNE/ PACM-βCD or 10 μM free HNE were added to the complete medium. After 5, 15, 30 min, aliquots of medium were analyzed by HPLC. **p≤0.01 vs. HNE. (B) HNE disappearance in HL-60 cell suspension. 10 μM HNE/ PACM-βCD or 10 μM free HNE were added to the cell culture. After 5, 15, 30 min, aliquots of medium were analyzed by HPLC. *p≤0.05 vs. HNE; **p≤0.01 vs. HNE.

Figure 10 Cell uptake of fluorescent PACM-βCD. HL-60, PC3 and A375 cells were incubated with the compound for the indicated times and then analyzed by confocal laser scanning microscopy without fixation. Images were obtained by using plan neofluar lens 20x/0.5 and 40x/0.75 (zoom 2X) in the insets (see Material and Methods section).

Figure 11 Detection of HNE-His adducts by immunofluorescence. HL-60 cells were incubated with 10 μM free HNE or 10 μM HNE/PACM-βCD. After 5, 15 and 45 min cells were harvested, exposed to the anti-HNE-His antibody and HNE-protein adducts were detected by using a secondary FITC-conjugated antibody. Images were obtained by using plan neofluar lens 40x/0.75.

Figure 12 HNE/PACM-βCD effect on A375 melanoma invasion in a 3D tissue model. Culture inserts were incubated in duplicate with serum-free medium containing 10 μM HNE/PACM-βCD (HNE/PACM-βCD), free 10 μM HNE (HNE), PACM-βCD, at dilution corresponding to that of HNE-loaded inclusion complex, or PBS for control (Control). Inserts were supplemented with fresh medium containing the corresponding formulations every other day. Representative sections from each treatment, stained with H&E, at day 8 is shown. The top bright red layer represents the epidermis; the next layer of cells with dark blue nuclei represents the melanocyte layer; and the bottom largely unstained area represents the fibroblast-contracted collagen dermal substrate. Serial sections were observed using a 10x/1.30 NA objective lens.
Figure 13 HNE/PACM-βCD inhibits proliferation of A375 melanoma cells in a 3D tissue model. Culture inserts were incubated in duplicate with serum-free medium containing 10 μM HNE/PACM-βCD (HNE/PACM-βCD), free 10 μM HNE (HNE), PACM-βCD, at dilution corresponding to that of HNE-loaded inclusion complex, or PBS for control (Control). Sections were examined for S100 and Ki-67 expression, by immunohistochemistry. Representative sections from each treatment at day 8 is shown. Serial sections were observed using a 10x/1.30 NA objective lens.

Figure 14 Quantitative analysis of the immunohistochemical results (see fig. 12) depicting the differences in the expression of S100, Ki-67, in 3D tissue cultures treated with 10 μM HNE/PACM-βCD (HNE/PACM-βCD), free 10 μM HNE (HNE), PACM-βCD, at dilution corresponding to that of HNE-loaded inclusion complex, or PBS for control (Control). Results are expressed in percentage with respect to control. **p<0.01 vs. control.
FIG 1
fig2
HL-60

10 μM

5 μM

1 μM

U937

Abs (570 nm)

Abs (570 nm)

Abs (570 nm)

time (hours)

time (hours)

time (hours)

fig4
HT-29
10 μM
5 μM
1 μM

RenCa

fig5
fig6
fig7
fig8
fig9
fig10
fig11
fig12
fig13
fig14